Moderna Inc
MRNAToday
+2.15%
5 Days
+9.31%
1 Month
+2.42%
6 Months
+47.23%
Year to Date
+119.32%
1 Year
+130.83%
Recent
Analysis
Earnings
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement
• Gilead Sciences shares fell following a failed Phase 3 solid tumor clinical trial. • Strong employment data increased Treasury yields, pressuring biotech sector valuations today. • Analysts may lower earnings forecasts due to delays in oncology portfolio sales timelines.
AstraZeneca PLC Stock (AZN) Moved Down by 3.50% on Jul 10: Key Drivers Unveiled
• AstraZeneca shares declined following a failed late-stage oncology trial endpoint. • Increased regulatory scrutiny and pricing pressures have impacted investor sentiment. • Analysts lowered valuations citing execution risks and potential earnings guidance revisions.
Moderna Inc Stock (MRNA) Moved Down by 8.01% on Jul 10: Facts Behind the Movement
• Moderna faces downward stock pressure due to revised management guidance on respiratory vaccine revenue. • Concerns regarding late-stage clinical trial timelines and efficacy data have increased investor uncertainty. • The company reported $1.94 billion in annual revenue and a net loss of $2.82 billion.
Merck & Co Inc Stock (MRK) Closed Up by 3.16% on Jul 2: What Signal Does It Send?
• Bank of America and Scotiabank raised price targets for Merck shares. • Strategic diversification and new drug assets mitigate concerns regarding the Keytruda patent cliff. • Merck continues upward momentum despite terminating an experimental Alzheimer’s drug trial.
Johnson & Johnson Stock (JNJ) Closed Up by 3.39% on Jul 2: What Investors Need To Know
• Johnson & Johnson reached a 52-week high amid positive pipeline and oncology portfolio growth. • Easing talc litigation risks and robust underlying fundamentals helped remove previous stock valuation overhangs. • Institutional investors rotated capital into Johnson & Johnson, favoring its strong defensive asset dynamics.
Amgen Inc Stock (AMGN) Moved Up by 3.01% on Jul 2: Key Drivers Unveiled
• A federal judge blocked a Colorado price cap on Amgen's drug Enbrel. • Concerns over Tavneos data integrity and Corlanor recalls caused intraday stock volatility. • Analysts maintain focus on long-term potential for pipeline drugs MariTide and olpasiran.
Moderna Inc's Score
Media Coverage
Analyst Rating
Moderna Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Moderna Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 6.74% |
| Vanguard Capital Management, LLC | 5.76% |
| BlackRock Institutional Trust Company, N.A. | 5.30% |
| Baillie Gifford & Co. | 5.04% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.49% |
| Investment Advisor/Hedge Fund | 14.13% |
| Hedge Fund | 10.11% |
| Corporation | 4.56% |
Related Instruments
Popular Instruments
